NO-1886 decreases ectopic lipid deposition and protects pancreatic beta cells in diet-induced diabetic swine
in Journal of EndocrinologySearch for other papers by W Yin in
Current site
Google Scholar
PubMed
Search for other papers by D Liao in
Current site
Google Scholar
PubMed
Search for other papers by M Kusunoki in
Current site
Google Scholar
PubMed
Search for other papers by S Xi in
Current site
Google Scholar
PubMed
Search for other papers by K Tsutsumi in
Current site
Google Scholar
PubMed
Search for other papers by Z Wang in
Current site
Google Scholar
PubMed
Search for other papers by X Lian in
Current site
Google Scholar
PubMed
Search for other papers by T Koike in
Current site
Google Scholar
PubMed
Search for other papers by J Fan in
Current site
Google Scholar
PubMed
Search for other papers by Y Yang in
Current site
Google Scholar
PubMed
Search for other papers by C Tang in
Current site
Google Scholar
PubMed
The synthetic compound NO-1886 (ibrolipim) is a lipoprotein lipase activator that has been proven to be highly effective in lowering plasma triglycerides. Recently, we found that NO-1886 also reduced plasma free fatty acids and glucose in high-fat/high-sucrose diet-induced diabetic rabbits. In the current study, we investigated the effects of NO-1886 treatment on ectopic lipid deposition and the islet pathology in miniature swine fed a high-fat/high-sucrose diet. Our results showed that feeding this diet to miniature swine caused insulin resistance, increased lipid deposition in non-adipose tissue, such as in the heart, skeletal muscle, liver and pancreas, and also caused pancreatic beta cell damage. However, supplementing 1% NO-1886 (200 mg/kg per day) into the high-fat/high-sucrose diet decreased ectopic lipid deposition, improved insulin resistance, and alleviated the beta cell damage. These results suggest that improvement of lipid disorder, non-adipose tissue steatosis and insulin resistance may be very important for the protection of beta cell damage. Therefore, NO-1886 is potentially beneficial for the treatment of insulin-resistance syndrome.
Journal of Endocrinology is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
| Sept 2018 onwards | Past Year | Past 30 Days | |
|---|---|---|---|
| Full Text Views | 689 | 437 | 33 |
| PDF Downloads | 135 | 59 | 4 |
Online ISSN: 1479-6805
Print ISSN: 0022-0795
Strengthening biomedical communities
to advance science and health
CONTACT US
Bioscientifica Ltd | Starling House | 1600 Bristol Parkway North | Bristol BS34 8YU | UK
Bioscientifica Ltd | Registered in England no 3190519